Breaking News Instant updates and real-time market news.

AGN

Allergan

$184.90

-1.04 (-0.56%)

, EDIT

Editas Medicine

$29.05

0.37 (1.29%)

16:06
08/06/18
08/06
16:06
08/06/18
16:06

Allergan subsidiary to commercialize Editas Medicine's EDIT-101

Allergan (AGN) and Editas Medicine (EDIT) announced that Allergan's wholly-owned subsidiary, Allergan Pharmaceuticals International, has exercised its option to develop and commercialize EDIT-101 globally for the treatment of LCA10. Additionally, the two companies announced that Editas Medicine has exercised its option to co-develop and share equally in the profits and losses from EDIT-101 in the United States. Under the terms of the option agreement signed in March 2017, Allergan has paid Editas Medicine a fee of $15M in conjunction with the exercise of its option. Editas Medicine is eligible to receive an additional $25M from Allergan upon acceptance of an investigational new drug, or IND, application for EDIT-101 by the FDA.

AGN

Allergan

$184.90

-1.04 (-0.56%)

EDIT

Editas Medicine

$29.05

0.37 (1.29%)

  • 06

    Aug

AGN Allergan
$184.90

-1.04 (-0.56%)

08/06/18
CANT
08/06/18
NO CHANGE
Target $180
CANT
Neutral
Allergan depression drugs have billion dollar potential, says Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen believes Two of Allergan's depression drugs in development, rapastinel and AGN-241751, have billions of dollars in peak sales potential. These two opportunities are still underappreciated by the Street, Chen tells investors in a research note. She expects positive data for these treatments but keeps a Neutral rating on Allergan shares with a $180 price target.
08/03/18
08/03/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. ALLERGAN UPGRADED TO BUY: Mizuho analyst Irina Koffler upgraded Allergan (AGN) to Buy from Neutral and raised her price target for the shares to $210 from $194. The analyst views Allergan's risk/reward more favorably following the company's "strong" beat and raise quarter and the delayed introduction of Restasis generics. Allergan is up 1.2% in late morning trading. NEEDHAM UPS TRIPADVISOR TO HOLD: Needham analyst Laura Martin upgraded TripAdvisor (TRIP) to Hold from Underperform, saying that while the company's pivot to competing as an online travel agent has failed, its focus to grow its non-hotel businesses is a "higher ROI idea". FLOOR & DECOR DOWNGRADED AT JPMORGAN, PIPER: JPMorgan analyst Christopher Horvers downgraded Floor & Decor (FND) to Neutral from Overweight and lowered his price target for the shares to $45 from $59. The "story shift" taking place is likely to keep the shares in "purgatory," Horvers said following the company's Q2 results. Piper Jaffray analyst Peter Keith also downgraded Floor & Decor to Neutral and lowered his price target for the shares to $39 from $58. The analyst admitted his June upgrade of the stock was wrong following Floor & Decor's Q2 miss and guide down. Floor & Decor is down 6.4% in late morning trading. LUNA CUT TO MARKET PERFORM AT NORTHLAND: Northland analyst Tim Savageaux downgraded Luna Innovations (LUNA) to Market Perform from Outperform as he sees the shares reflecting the value of the "well executed" sale of the Opto Solutions unit at current levels. CANACCORD INITIATES TESLA WITH A HOLD: Canaccord analyst Jed Dorsheimer initiated Tesla (TSLA) with a Hold rating as he sees several risks around the company's financing, cash burn, and general maturity in the industry. Catalysts that could de-risk the shares include shifts in corporate governance, consistent production, and "a CEO who is not working 120 hours per week to hold things together," said Dorsheimer, who set a $336 price target on Tesla shares. BWS SAYS ARLO IPO ESTABLISHES VALUATION CASE FOR NETGEAR: BWS Financial analyst Hamed Khorsand said the pricing of Arlo Technologies' (ARLO) IPO establishes a valuation case for Netgear (NTGR). The analyst believes the IPO pricing gives some context to what Netgear's stake is worth and affirms his sum-of-parts reasoning for owning Netgear shares. He kept a Buy rating on the stock with a $64.50 price target.
08/03/18
08/03/18
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Allergan (AGN) upgraded to Buy from Neutral at Mizuho with analyst Irina Koffler saying she views Allergan's risk/reward more favorably following the company's "strong" beat and raise quarter and the delayed introduction of Restasis generics. 2. Pacira (PCRX) upgraded to Buy from Hold at Needham with analyst Serge Belanger citing "strong" Q2 performance of Exparel, where sales growth is accelerating while the company engages more of the anesthesiologist community. 3. Entergy (ETR) upgraded to Buy from Neutral at UBS with analyst Daniel Ford saying the stock no longer warrants a discount associated with nuclear decommissioning and operating performance risk. 4. Eversource (ES) upgraded to Neutral from Underperform at BofA/Merrill with analyst Julien Dumoulin-Smith saying the story has been de-risked with no major capex projects left. 5. TripAdvisor (TRIP) upgraded to Hold from Underperform at Needham with analyst Laura Martin saying while the company's pivot to competing as an online travel agent has failed, its focus to grow its non-hotel businesses is a "higher ROI idea." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/03/18
MZHO
08/03/18
UPGRADE
Target $210
MZHO
Buy
Allergan upgraded to Buy from Neutral at Mizuho
Mizuho analyst Irina Koffler upgraded Allergan to Buy and raised her price target for the shares to $210 from $194. The Botox maker closed yesterday up 29c to $184.28. The analyst views Allergan's risk/reward more favorably following the company's "strong" beat and raise quarter and the delayed introduction of Restasis generics. Further, the company's September 14 Aesthetics Day could drive multiple expansion in the stock, Koffler tells investors in a research note. The analyst likes Allergan's "dominance" in a growing cash pay market, low exposure to near-term rebating pressure, and improving operating margins after "unexpected" strength in the body contouring products in Q2.
EDIT Editas Medicine
$29.05

0.37 (1.29%)

07/18/18
JEFF
07/18/18
NO CHANGE
Target $40
JEFF
Buy
Study in Nature Biotech has limited readthrough to Intellia, says Jefferies
A new Nature Biotech publication highlights important safety points, but due to the methods/model systems used, the paper has limited readthrough to Intellia Therapeutics (NTLA), Editas Medicine (EDIT) and Crispr Therapeutics (CRSP) programs advancing to the clinic, Jefferies analyst Maury Raycroft tells investors in a research note. The analyst believes the experiments used in the paper were not representative and may not have direct implications to current gene-editing clinical-directed strategies. The paper is another example of using a non-optimal model system with too many variables, Raycroft contends. He keeps a Buy rating on Intellia with a $40 price target.
06/11/18
MSCO
06/11/18
NO CHANGE
MSCO
Equal Weight
Editas CRISPR-related cancer risks seem overblown, says Morgan Stanley
After studies published in Nature Medicine by Novartis (NVS) and the Karolinska Institute suggested an increased risk of cancer that could result from editing genomes with CRISPR-Cas9, Morgan Stanley analyst Matthew Harrison said the concerns are theoretical and noted that STAT's article on the subject does not provide any link to an increased risk for CRISPR activation of p53 versus natural activation when DNA breaks. Harrison thinks theoretical concerns will continue to arise regarding gene editing until the first substantial set of clinical data is generated, but he does not see any direct concerns for Editas Medicine (EDIT) and expects the stock to recover in the coming days. He keeps an Equal Weight rating and $39 price target on Editas shares. Morgan Stanley does not cover Intellia Therapeutics (NTLA) or Crispr Therapeutics (CRSP), which have also seen weakness following the Nature Medicine publications.
03/07/18
JMPS
03/07/18
NO CHANGE
Target $67
JMPS
Outperform
Editas Medicine price target raised to $67 from $40 at JMP Securities
JMP Securities analyst Michael King noted that Editas Medicine (EDIT) management highlighted with the Q4 earnings report that the company remains on track for a mid-2018 IND filing for EDIT-101 in LCA10. Management also highlighted that collaborator Juno Therapeutics (JUNO) plans to begin IND-enabling studies this year and to begin human clinical trials next year to treat human papillomavirus-associated solid tumors with T cells engineered using Editas' technology. Following the company's report of pipeline progress, and his own comparable company analysis, King raised his price target on Editas to $67 from $40 and keeps an Outperform rating on the shares.
03/07/18
LEHM
03/07/18
NO CHANGE
Target $46
LEHM
Overweight
Editas Medicine price target raised to $46 from $28 at Barclays
Barclays analyst Gena Wang raised her price target for Editas Medicine (EDIT) to $46 citing the company's technology platform and pipeline value. Several recent events, including the acquisitions of Kite and Juno and Sangamo (SGMO) collaboration with Gilead (GILD), validated the value of cell therapy and the potential of gene-editing technologies to serve as a powerful tool in developing next-generation products, Wang tells investors in a research note. She sees "strong upside potential" in Editas shares and keeps an Overweight rating on the name.

TODAY'S FREE FLY STORIES

FB

Facebook

$164.25

-1.83 (-1.10%)

, GOOG

Alphabet

$1,204.85

-26.86 (-2.18%)

08:18
03/23/19
03/23
08:18
03/23/19
08:18
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

FB

Facebook

$164.25

-1.83 (-1.10%)

GOOG

Alphabet

$1,204.85

-26.86 (-2.18%)

GOOGL

Alphabet Class A

$1,206.00

-30.38 (-2.46%)

TWTR

Twitter

$32.98

0.37 (1.13%)

GM

General Motors

$36.51

-0.84 (-2.25%)

AMD

AMD

$26.43

-1.47 (-5.27%)

INTC

Intel

$53.20

-1.41 (-2.58%)

MRVL

Marvell

$19.69

-1.11 (-5.34%)

MCHP

Microchip

$85.50

-1.83 (-2.10%)

MU

Micron

$41.68

-2.32 (-5.27%)

NVDA

Nvidia

$177.40

-6.52 (-3.55%)

QCOM

Qualcomm

$56.71

-1.05 (-1.82%)

TXN

Texas Instruments

$109.51

-2.68 (-2.39%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 27

    Mar

  • 27

    Mar

  • 03

    Apr

  • 04

    Apr

  • 23

    Apr

  • 25

    Apr

  • 25

    Apr

  • 29

    Apr

  • 29

    Apr

  • 30

    Apr

  • 01

    May

  • 28

    May

  • 04

    Jun

  • 05

    Jun

  • 27

    Oct

21:30
03/22/19
03/22
21:30
03/22/19
21:30
General news
Breaking General news story  »

Chicago Federal Reserve…

21:15
03/22/19
03/22
21:15
03/22/19
21:15
General news
Breaking General news story  »

Atlanta Federal Reserve…

PLNT

Planet Fitness

$66.76

-0.825 (-1.22%)

18:44
03/22/19
03/22
18:44
03/22/19
18:44
Hot Stocks
Planet Fitness CEO: We have a streamlined business model »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRDM

Iridium

$26.40

-0.38 (-1.42%)

18:22
03/22/19
03/22
18:22
03/22/19
18:22
Hot Stocks
Iridium CEO: We've doubled our bottom line over the past eight years »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

, SPX

S&P 500

$0.00

(0.00%)

18:05
03/22/19
03/22
18:05
03/22/19
18:05
General news
Sen. Sanders calls on White House to make Mueller report public »

U.S. Senator and…

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$279.37

-5.26 (-1.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IDTI

Integrated Device

$47.80

-0.04 (-0.08%)

, RNECY

Renesas

$0.00

(0.00%)

18:02
03/22/19
03/22
18:02
03/22/19
18:02
Hot Stocks
Integrated Device, Renesas receive final approval for merger »

Renesas Electronics…

IDTI

Integrated Device

$47.80

-0.04 (-0.08%)

RNECY

Renesas

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

, SPX

S&P 500

$0.00

(0.00%)

17:48
03/22/19
03/22
17:48
03/22/19
17:48
General news
Senator Warren urges AG Barr to release Mueller report to the public »

U.S. Senator and…

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$279.37

-5.26 (-1.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$362.49

-10.2 (-2.74%)

17:44
03/22/19
03/22
17:44
03/22/19
17:44
Hot Stocks
Lawmaker urges FAA, Boeing workers to utilize whistleblower page »

Chair of the House…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

GLD

SPDR Gold Shares

$123.97

0.29 (0.23%)

17:44
03/22/19
03/22
17:44
03/22/19
17:44
Hot Stocks
SPDR Gold Shares holdings rise to 781.03MT from 778.09MT »

This is the highest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

17:40
03/22/19
03/22
17:40
03/22/19
17:40
General news
Weekly CFTC Commitment of Traders highlights »

10-YEAR U.S. TREASURY net…

ONEXF

Onex

$0.00

(0.00%)

17:35
03/22/19
03/22
17:35
03/22/19
17:35
Hot Stocks
Onex to acquire Gluskin Sheff »

Onex Corporation and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DZSI

DASAN Zhone

$12.10

-0.12 (-0.98%)

17:35
03/22/19
03/22
17:35
03/22/19
17:35
Syndicate
Breaking Syndicate news story on DASAN Zhone »

DASAN Zhone files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

REPH

Recro Pharma

$9.73

0.1 (1.04%)

17:35
03/22/19
03/22
17:35
03/22/19
17:35
Hot Stocks
Breaking Hot Stocks news story on Recro Pharma »

Recro Pharma trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Mar

DZSI

DASAN Zhone

$12.10

-0.12 (-0.98%)

17:35
03/22/19
03/22
17:35
03/22/19
17:35
Syndicate
Breaking Syndicate news story on DASAN Zhone »

DASAN Zhone files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

, SPX

S&P 500

$0.00

(0.00%)

17:34
03/22/19
03/22
17:34
03/22/19
17:34
General news
White House says hasn't received, been briefed on Mueller report, WSJ says »

Following confirmation…

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$279.37

-5.26 (-1.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CATS

Catasys

$13.19

-0.39 (-2.87%)

17:26
03/22/19
03/22
17:26
03/22/19
17:26
Syndicate
Breaking Syndicate news story on Catasys »

Catasys files $50M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USWS

U.S. Well Services

$7.74

-0.54 (-6.52%)

17:20
03/22/19
03/22
17:20
03/22/19
17:20
Syndicate
Breaking Syndicate news story on U.S. Well Services »

U.S. Well Services files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADIL

Adial Pharmaceuticals

$2.97

-0.12 (-3.88%)

17:17
03/22/19
03/22
17:17
03/22/19
17:17
Syndicate
Breaking Syndicate news story on Adial Pharmaceuticals »

Adial Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STNG

Scorpio Tankers

$18.85

-0.66 (-3.38%)

17:16
03/22/19
03/22
17:16
03/22/19
17:16
Syndicate
Breaking Syndicate news story on Scorpio Tankers »

Scorpio Tankers files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NAVB

Navidea

$0.14

-0.0001 (-0.07%)

17:13
03/22/19
03/22
17:13
03/22/19
17:13
Syndicate
Navidea offers to sell $3M in common stock for existing shareholder »

Navidea…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

, SPX

S&P 500

$0.00

(0.00%)

17:11
03/22/19
03/22
17:11
03/22/19
17:11
General news
Mueller delivers Russia report to AG William Barr, CNBC reports »

Special counsel Robert…

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$279.37

-5.26 (-1.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$362.49

-10.2 (-2.74%)

, NOC

Northrop Grumman

$268.29

-4.01 (-1.47%)

17:10
03/22/19
03/22
17:10
03/22/19
17:10
Hot Stocks
Boeing awarded $4.14B Missle Defense Agency contract »

Boeing (BA) has been…

BA

Boeing

$362.49

-10.2 (-2.74%)

NOC

Northrop Grumman

$268.29

-4.01 (-1.47%)

RTN

Raytheon

$179.98

-1.94 (-1.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    May

AAPL

Apple

$190.97

-4.1 (-2.10%)

17:09
03/22/19
03/22
17:09
03/22/19
17:09
Periodicals
Partners not sure how Apple plans to package, price video service, CNBC says »

Apple is set to announce…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

RIVE

Riverview Financial

$11.20

(0.00%)

17:05
03/22/19
03/22
17:05
03/22/19
17:05
Syndicate
Breaking Syndicate news story on Riverview Financial »

Riverview Financial files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.